Physician profile
Philip Gauslin
NPI 1962427732
$2,814.84
in general payments reported to CMS, 2019-2025
24 companies · $886 in 2025
The $886 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $197 · 2023: $599 · 2024: $1,134 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.59 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.25 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $484.06 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $363.42 | 2022-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $254.33 | 2024-2025 | |
| Glaxosmithkline, LLC. | $179.08 | 2022-2025 | Shingrix, Arexvy |
| Lundbeck LLC | $142.12 | 2024-2025 | Vyepti, Rexulti |
| Shield Therapeutics INC | $130.04 | 2023-2024 | Accrufer |
| Abbvie INC. | $99.64 | 2022-2024 | |
| Pfizer INC. | $85.13 | 2023-2025 | |
| Exact Sciences Corporation | $72.32 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $71.67 | 2023 | Rexulti |
| Amgen INC. | $65.00 | 2022-2025 | Repatha, Repatha, Otezla |
| Philips North America LLC | $57.42 | 2024 | (Ck7) Extended Holter |
| Esperion Therapeutics, INC. | $35.21 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $32.59 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.22 | 2022-2025 | Veozah |
| Antares Pharma, INC. | $28.49 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Ars Pharmaceuticals Operations, INC. | $25.21 | 2025 | Neffy |
| Vertex Pharmaceuticals Incorporated | $19.21 | 2025 | |
| Merck Sharp & Dohme LLC | $18.28 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sumitomo Pharma America, INC. | $17.77 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $16.11 | 2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.49 | 2024 | Jardiance |
| Dynavax Technologies Corporation | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Gauslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.